XORTX Therapeutics Inc.

XORTX Therapeutics is a clinical-stage biopharmaceutical company headquartered in Calgary, Canada, focused on developing therapies for gout and progressive kidney diseases. The company's pipeline includes XRx-026, a Phase 3 candidate for gout treatment, and XRx-008, a Phase 2 program targeting autosomal dominant polycystic kidney disease. Additional candidates under development are XRx-101, in Phase 2 for acute kidney injury associated with respiratory virus infection, and XRX-225, in preclinical stages for type 2 diabetic nephropathy. The company holds a license agreement with the University of Florida Research Foundation for use of a uric acid lowering agent in treating insulin resistance.

As a late-stage clinical company, XORTX does not currently generate meaningful revenue from product sales. The company's operations are supported through research and development activities, with primary focus on advancing its clinical candidates through regulatory pathways. Geographic reach is centered in Canada, with research partnerships extending to academic institutions in the United States.